Advances in Personalized Medicine Personalized Neoantigen Vaccines and Immune Checkpoint Inhibitor Combination Treatments

Abstract

Background: Solid tumor malignancies are a cause of mortality in adults, with growing prevalence in young adults. Chemotherapies in combination with immune checkpoint inhibitors have been shown to induce responses in these tumors through T cell responses, however non-responders in the clinical setting have been observed.

Methods: PubMed searches were conducted with the keywords “Cancer vaccines”, “Personalized vaccines,” “tumor neoantigens” and “cancer immunotherapies.”

Results: Personalized neoantigen vaccines constructed from primarily DNA, RNA and peptides have been shown to generate CD4+ and CD8+ T cell responses, resulting in delay in tumor growth and tumor regression. Created from tumor specific antigens, they are unique to each patient. Experiments detecting for T cell responses and preclinical models have provided evidence for the safety, feasibility and clinical efficacy of personalized neoantigen vaccines and immune checkpoint inhibitor combination treatments.

Conclusion: Future research can be directed to developing personalized neoantigen vaccines-ICI combination treatments for treatment of cancer and hematologic malignancies.

---

Certificate of Publication

---

---

---

Copyright

© 2025 Hays P. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Hays P. Advances in Personalized Medicine: Personalized Neoantigen Vaccines and Immune Checkpoint Inhibitor Combination Treatments. J Biomed Res Environ Sci. 2025 Feb 28; 6(2): 172-179. doi: 10.37871/ jbres2069, Article ID: JBRES2069, Available at: https://www.jelsciences.com/articles/jbres2069.pdf

---

Subject area(s)

References

---